Overview
- Paul Devlin, who testified Tuesday, accepted the trust missed a chance to act after an August 2022 fatal attack by a former patient and said an audit of unsafe discharges that September might have flagged Valdo Calocane and helped avoid the June 2023 killings.
- Outgoing chief executive Ifti Majid told the inquiry Monday that delays in carrying out review recommendations were a serious failure of governance and confirmed the trust had not apologized to a woman who broke her spine fleeing Calocane in 2020.
- Former chief executive John Brewin acknowledged Monday that improvements under his tenure were insufficient, and his 2021 email warned services were not safe as the Care Quality Commission later considered urgent enforcement after a January 2026 inspection.
- The trust disclosed Monday that no staff disciplinary cases linked to Calocane’s care have been completed nearly three years on, saying it paused proceedings after the inquiry was announced and will revisit referrals to medical and nursing regulators once hearings end.
- The inquiry enters its final weeks with more senior leaders due to give evidence, a leadership change set for June as Mark Axcell replaces Majid, and continued regulatory pressure as the CQC’s detailed inspection report remains pending.